Why injection pens must never be shared

The warning, label by label

All of the multi-dose GLP-1 pens sold in the US carry the instruction, but not always in the same place. The table lists where each US label puts it, checked against the documents on 20 October 2026.

The Ozempic®, Wegovy®, Victoza®, Mounjaro® and Zepbound® labels give the same kind of reason: sharing can pass on blood-borne pathogens, meaning germs carried in blood. Saxenda® words it more generally, as a possible risk of passing on an infection ^[6].

Why a new needle is not enough

The striking part of the warning is the phrase “even if the needle is changed”. Many people assume the needle is the only part that touches another person. The labels rule that assumption out and treat the whole pen as belonging to one patient ^[1][5].

Studies of insulin pens show why. In a French study of 120 people using insulin pens, material that was not inert, including skin and epithelial cells, turned up in 58% of the cartridges after an injection, not only in the needles ^[12]. In a US hospital study, 7 of 125 insulin pens returned after discharge held cells or free haemoglobin in the medicine itself; the authors concluded that infection could pass between patients sharing a cartridge even with a new needle each time ^[13].

These are insulin studies, not GLP-1 studies, and finding cells in a cartridge is not the same as finding an infection. When a military hospital found that single-patient pens had been used on several inpatients, testing of 1,501 people found no clear evidence of blood-borne transmission ^[14]. The labels do not wait for proof of harm: they treat any shared pen as a risk.

Which devices it covers, and which it does not

The warning is attached to multi-dose pens, the ones that hold several doses and are used again and again. The Ozempic® pen is described as single-patient-use with multiple weekly doses, and the Mounjaro®, Zepbound® KwikPen and Wegovy® FlexTouch® each hold four weekly doses ^[1][2][3].

Single-dose pens are a different design: they are used once and thrown away, and the Wegovy® instructions say not to reuse the pen ^[2]. The Canadian patient information for Trulicity®, which comes only in single-dose pens, still tells patients not to share the pen or needles, for the same infection reason ^[10]. For vials, the Mounjaro® label asks that each injection be drawn up with a fresh syringe and a fresh needle ^[3].

The general rule in every Medication Guide also applies to tablets: the medicine is not to be given to someone else, even someone with the same symptoms ^[1].

How the rule appears in Europe and Canada

The EU product information for Ozempic® and Wegovy® puts it in the handling section, 6.6, in a single line: the pen is for use by one person only. The same section explains that removing the needle after each injection helps prevent blocked needles, contamination, infection, leaking and inaccurate doses, and the package leaflet tells patients never to share their pen or needles ^[8][9].

The Canadian monograph for Trulicity® includes the warning in its Patient Medication Information, the Canadian name for the patient leaflet ^[10]. The wording differs from one document to another, but none of them allows a pen to pass between people.

Needles and syringes too

The Instructions for Use for Ozempic® and Wegovy® say to use a new needle for every injection and never to reuse or share needles, giving the same infection reason. A new needle also reduces the risk of contamination, leaking and a blocked needle that can deliver the wrong dose ^[1][2].

The Ozempic® label adds that the needle should be removed after each injection and the pen stored without a needle attached ^[1]. For vials, the same logic applies to syringes: one person, one use.

What the FDA sees in error reports

An FDA and Institute for Safe Medication Practices presentation on pen injectors lists using the same insulin pen for more than one patient among the errors reported to them, and attributes it to a lack of knowledge. Its prevention advice is that pens are labelled for single-patient use and should never be shared ^[11].

The same presentation lists related errors worth knowing: reusing needles, forgetting to remove the inner needle cap, using a pen or its cartridge as if it were a vial, and using a pen after its in-use date ^[11].

More than one user in a home

It is common for two people in the same household to use the same medicine. The FDA presentation notes that having several pens is one of the situations behind wrong-drug and wrong-strength errors, and that the product name and strength are printed on every pen and carton, sometimes requiring you to turn the pen to read them ^[11].

The labels ask that pens be kept in their original carton ^[1][3]. Keeping each person’s pens in their own carton, and checking the name and strength before each injection, keeps one person’s pen from being picked up by mistake. Two KwikPens of the same strength are still two separate pens, one for each person.

When someone else gives the injection

Help with injecting is allowed. The Mounjaro® label, for example, says another person can give the injection in the back of the upper arm, and asks that patients and caregivers be trained before the first dose ^[3]. It also says the KwikPen is not recommended for people with visual impairment, or for children injecting themselves, unless their healthcare provider decides they can use it properly ^[3].

A caregiver helping does not change whose pen it is. The pen, the needle and the dose belong to the patient.

If a pen or needle may have been shared

If someone else used your pen, or you used theirs, the labels give no way to make that pen safe again; talk to your pharmacist or prescriber before the next dose ^[1]. If a used needle from another person went into your skin, MedlinePlus describes an HIV prevention treatment called PEP that must start within 72 hours of a possible exposure, including exposure through shared needles, and advises contacting a healthcare provider or emergency room right away ^[15].

Whether testing or treatment is needed is a decision for the clinician who sees you. Noting the date, the pen and whose it was helps that conversation.

Ozempic®, Wegovy®, FlexTouch®, Victoza® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.

When to get help